{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:40:33Z","timestamp":1791409233899,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,9,22]],"date-time":"2006-09-22T00:00:00Z","timestamp":1158883200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2007,3,2]]},"DOI":"10.1007\/s00213-006-0570-5","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T18:09:42Z","timestamp":1159898982000},"page":"805-811","source":"Crossref","is-referenced-by-count":54,"title":["Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait"],"prefix":"10.1007","volume":"191","author":[{"given":"Jose J.","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lome\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Font","family":"Mireia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Fernandez-Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,22]]},"reference":[{"key":"570_CR1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association (APA)","year":"1994","unstructured":"American Psychiatric Association (APA) (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Washington, USA","edition":"4"},{"key":"570_CR2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0925-4927(01)00085-3","volume":"107","author":"M Bernardo","year":"2001","unstructured":"Bernardo M, Parellada E, Lome\u00f1a F, Catafau A, Font M, G\u00f3mez J, Lopez-Carrero C, Gutierrez F, Pavia J, Salamero M (2001) Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline\u2013endpoint [123I] IBZM SPECT study. Psychiatry Research Neuroimaging 107:87\u201397","journal-title":"Psychiatry Research Neuroimaging"},{"key":"570_CR3","volume-title":"Handbuch der Geiteskrankheiten. Leipzig: Deutike)","author":"E Bleuler","year":"1911","unstructured":"Bleuler E (1911) Dementia praecox or the group of schizophrenias (trans. J. Zinkin: Dementia Praecox ode der Gruppe der Schizophrenien. In: Aschaffenburg PG (ed) Handbuch der Geiteskrankheiten. Leipzig: Deutike). International Universities Press, New York, 1950"},{"key":"570_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002590050374","volume":"26","author":"J Booij","year":"1999","unstructured":"Booij J, Tissingh G, Winogrodzca A, Van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171\u2013182","journal-title":"Eur J Nucl Med"},{"key":"570_CR5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1098-2396(200102)39:2<101::AID-SYN1>3.0.CO;2-1","volume":"39","author":"J Booij","year":"2001","unstructured":"Booij J, Bergmans P, Winogrodzca A, Speelman JD, Wolters E (2001a) Imaging of Dopamine Transporters with [123I] FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson\u2019s disease. Synapse 39:101\u2013108","journal-title":"Synapse"},{"key":"570_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","volume":"28","author":"J Booij","year":"2001","unstructured":"Booij J, Speelman J, Horstink MW, Wolters E (2001b) The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 28:266\u2013272","journal-title":"Eur J Nucl Med"},{"key":"570_CR7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s002590000372","volume":"27","author":"RA Bressan","year":"2000","unstructured":"Bressan RA, Pilowsky LS (2000) Imaging the glutamatergic system in vivo\u2014relevance to schizophrenia. Eur J Nucl Med 27:1723\u20131731","journal-title":"Eur J Nucl Med"},{"key":"570_CR8","doi-asserted-by":"crossref","unstructured":"Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18F-DOPA PET study. Neurology 43:552\u2013556","DOI":"10.1212\/WNL.43.3_Part_1.552"},{"key":"570_CR9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1176\/ajp.150.9.1343","volume":"150","author":"M Caliguri","year":"1993","unstructured":"Caliguri M, Lohr J, Jeste D (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 150:1343\u20131348","journal-title":"Am J Psychiatry"},{"key":"570_CR10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/mds.20112","volume":"19","author":"A Catafau","year":"2004","unstructured":"Catafau A, Tolosa E (2004) Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 19:1175\u20131182","journal-title":"Mov Disord"},{"key":"570_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247\u2013265","journal-title":"Schizophr Res"},{"key":"570_CR12","first-page":"1203","volume":"41","author":"PW Corrigan","year":"1990","unstructured":"Corrigan PW, Liberman RP, Engel JD (1990) From noncompliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 41:1203\u20131211","journal-title":"Hospital and Community Psychiatry"},{"key":"570_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-9964(02)00500-5","volume":"65","author":"AE Drew","year":"2003","unstructured":"Drew AE, Werling LL (2003) Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophr Res 65:47\u201355","journal-title":"Schizophr Res"},{"key":"570_CR14","volume-title":"Structured clinical interview for DSM-IV-Patients edition (SCID-P)","author":"MB First","year":"1994","unstructured":"First MB, Spitzer RL, Williams JBW, Gibbon M (1994) Structured clinical interview for DSM-IV-Patients edition (SCID-P). American Psychiatric Press, Washington, DC"},{"key":"570_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(95)00770-9","volume":"298","author":"I Gordon","year":"1996","unstructured":"Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298:27\u201330","journal-title":"Eur J Pharmacol"},{"key":"570_CR16","first-page":"338","volume-title":"Early clinical drug evaluation unit (ECDEU), vol 76","author":"W Guy","year":"1976","unstructured":"Guy W (1976) Early clinical drug evaluation unit (ECDEU), vol 76. National Institute of Mental Health, Rockville, USA, p 338"},{"key":"570_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","volume":"32","author":"MD Jibson","year":"1998","unstructured":"Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32:215\u2013228","journal-title":"J Psychiatr Res"},{"key":"570_CR18","first-page":"262","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fisbein S, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:262\u2013273","journal-title":"Schizophr Bull"},{"key":"570_CR19","volume-title":"Dementia praecox and paraphrenia","author":"E Kraepelin","year":"1919","unstructured":"Kraepelin E (1919) Dementia praecox and paraphrenia. University of Edinburgh, Edinburgh"},{"key":"570_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/appi.ajp.157.2.269","volume":"157","author":"A Laakso","year":"2000","unstructured":"Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, R\u00e4kk\u00f6l\u00e4inen V, Syv\u00e4lahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic na\u00efve patients with schizophrenia studied with PET. Am J Psychiatry 157:269\u2013271","journal-title":"Am J Psychiatry"},{"key":"570_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-9964(00)00095-5","volume":"52","author":"A Laakso","year":"2001","unstructured":"Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Siv\u00e4lahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115\u2013120","journal-title":"Schizophr Res"},{"key":"570_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0006-3223(99)00257-7","volume":"47","author":"M Laruelle","year":"2000","unstructured":"Laruelle M, Abi-Dargham A, Van Dyck C, Gil R, D\u2019Souza D, Krystal J, Seibyl J, Baldwin R, Innis R (2000) Dopamine and serotonin transporter in patients with schizophrenia: an imaging study with 123I-\u03b2CIT. Biol Psychiatry 47:371\u2013379","journal-title":"Biol Psychiatry"},{"key":"570_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0920-9964(00)00023-2","volume":"47","author":"J Lavalaye","year":"2001","unstructured":"Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken J, Gersons B, Van Royen E (2001) Dopamine transporter density in young patients with schizophrenia assessed with [123I] FP-CIT SPECT. Schizophr Res 47:59\u201367","journal-title":"Schizophr Res"},{"key":"570_CR24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0006-3223(99)00061-X","volume":"46","author":"D Lewis","year":"1999","unstructured":"Lewis D, Pierri J, Volk D, Melchitzky DS, Woo T (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616\u2013626","journal-title":"Biol Psychiatry"},{"key":"570_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2004.03.053","volume":"363","author":"S Li","year":"2004","unstructured":"Li S, Kim KY, Kim JH, Kin JH, Park MS, Bahk JY, Kim MO (2004) Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 363:29\u201332","journal-title":"Neurosci Lett"},{"key":"570_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/schbul\/16.1.97","volume":"16","author":"JA Lieberman","year":"1990","unstructured":"Lieberman JA, Kinon BL, Loebel AD (1990) Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 16:97\u2013110","journal-title":"Schizophr Bull"},{"key":"570_CR27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-005-2250-2","volume":"181","author":"JJ Mateos","year":"2005","unstructured":"Mateos JJ, Lome\u00f1a F, Parellada E, Font M, Fernandez E, Pavia J, Prats A, Pons F, Bernardo M (2005) Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181:401\u2013406","journal-title":"Psychopharmacology"},{"key":"570_CR28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1192\/bjp.168.2.221","volume":"168","author":"RG McCreadie","year":"1996","unstructured":"McCreadie RG, Thara R, Kamath D, Padmavati R, Latha S, Mathrubootham N, Menon S (1996) Abnormal movements in never medicated Indian patients with schizophrenia. Br J Psychiatry 168:221\u2013226","journal-title":"Br J Psychiatry"},{"key":"570_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1192\/bjp.181.4.321","volume":"181","author":"R McCreadie","year":"2002","unstructured":"McCreadie R, Padmavati R, Thara R, Srinivasan TN (2002) Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 181:135\u2013137","journal-title":"Br J Psychiatry"},{"key":"570_CR30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007611-199005000-00011","volume":"83","author":"LG Miller","year":"1990","unstructured":"Miller LG, Jankovic J (1990) Neuroleptic approach to drug-induced movement disorders: a study of 125 patients. South Med J 83:525\u2013532","journal-title":"South Med J"},{"key":"570_CR31","first-page":"269","volume":"4","author":"V Peralta","year":"2002","unstructured":"Peralta V, Cuesta M, Campos MS (2002) S\u00edntomas extrapiramidales en pacientes esquizofr\u00e9nicos nunca tratados con neurol\u00e9pticos. Aula M\u00e9dica Psiqui\u00e1trica 4:269\u2013280","journal-title":"Aula M\u00e9dica Psiqui\u00e1trica"},{"key":"570_CR32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archneur.1982.00510220042009","volume":"10","author":"AH Rajput","year":"1982","unstructured":"Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 10:644\u2013646","journal-title":"Arch Neurol"},{"key":"570_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1022405621365","volume":"23","author":"TA Reader","year":"1998","unstructured":"Reader TA, Ase AR, Huang N, Hebert C, Van Gelder NM (1998) Neuroleptics and dopamine transporters. Neurochem Res 23:73\u201380","journal-title":"Neurochem Res"},{"key":"570_CR34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0014-2999(84)90403-5","volume":"104","author":"E Richelson","year":"1984","unstructured":"Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277\u2013286","journal-title":"Eur J Pharmacol"},{"key":"570_CR35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-8993(95)00611-S","volume":"692","author":"R Rivest","year":"1995","unstructured":"Rivest R, Falardeau P, Di Paolo T (1995) Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:269\u2013272","journal-title":"Brain Res"},{"key":"570_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00406-005-0618-2","volume":"256","author":"GJ Schmitt","year":"2006","unstructured":"Schmitt GJ, Frodl T, Dresel S, La Fougere C, Bottlender R, Koutsouleris N, Hahn K, Moller Hj, Meisenzahl EM (2006) Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256:115\u2013121","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"570_CR37","first-page":"1641","volume":"154","author":"MV Seeman","year":"1997","unstructured":"Seeman MV (1997) Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154:1641\u20131647","journal-title":"J Psychiatry"},{"issue":"Suppl","key":"570_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW (1970) A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 212(Suppl):11\u201319","journal-title":"Acta Psychiatr Scand"},{"key":"570_CR39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00213-003-1700-y","volume":"173","author":"H Sjoholm","year":"2004","unstructured":"Sjoholm H, Bratlid T, Sundsfjord J (2004) 123I \u03b2-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology 173:27\u201331","journal-title":"Psychopharmacology"},{"key":"570_CR40","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00006231-200107000-00015","volume":"22","author":"K Tatsch","year":"2001","unstructured":"Tatsch K (2001) Imaging of the dopaminergic system in parkinsonism with SPECT. Nucl Med Commun 22:819\u2013827","journal-title":"Nucl Med Commun"},{"key":"570_CR41","first-page":"31","volume":"40","author":"K Tatsch","year":"1999","unstructured":"Tatsch K, Scherer J, Linke R, Kerner M, Hahn K (1999) Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.). J Nucl Med 40:31","journal-title":"J Nucl Med"},{"key":"570_CR42","first-page":"1143","volume":"39","author":"G Tissingh","year":"1998","unstructured":"Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, Van Royen EA (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-ebeta-(4-iodophenyl)-tropane SPECT in healthy controls and early-stage, drug-na\u00efve Parkinson\u2019s disease. J Nucl Med 39:1143\u20131148","journal-title":"J Nucl Med"},{"key":"570_CR43","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/mds.10575","volume":"18","author":"E Tolosa","year":"2003","unstructured":"Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18:S28\u2013S33","journal-title":"Mov Disord"},{"key":"570_CR44","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1523\/JNEUROSCI.20-18-07067.2000","volume":"20","author":"H Tsukada","year":"2000","unstructured":"Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T (2000) Cholinergic neuronal modulation alters dopamine d2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci 20:7067\u20137073","journal-title":"J Neurosci"},{"key":"570_CR45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1471-4159.1993.tb03174.x","volume":"60","author":"M Valchar","year":"1993","unstructured":"Valchar M, Hanbauer I (1993) Comparison of 3HWIN 35,428 binding, a marker for dopamine transporter, in embrionyc mesencephalic neuronal cultures with striatal membranes of adult rats. J Neurochem 60:469\u2013476","journal-title":"J Neurochem"},{"key":"570_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00019442-200201000-00005","volume":"10","author":"Ch Dyck Van","year":"2002","unstructured":"Van Dyck Ch, Seibyl J, Malison R, Laruelle M, Zoghhi S, Baldwin R, Innis R (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects and hemispheric asymmetries. Am J Geriatr Psychiatry 10:36\u201346","journal-title":"Am J Geriatr Psychiatry"},{"key":"570_CR47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002130051163","volume":"147","author":"NPLG Verhoeff","year":"1999","unstructured":"Verhoeff NPLG (1999) Radiotracers imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 147:217\u2013249","journal-title":"Psychopharmacology"},{"key":"570_CR48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","volume":"73","author":"Z Walker","year":"2002","unstructured":"Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CLE (2002) Differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134\u2013140","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"570_CR49","first-page":"304","volume":"24","author":"A Wolff","year":"1999","unstructured":"Wolff A, O\u2019Driscoll G (1999) Motor deficits and schizophrenia: the evidence from neuroleptic-na\u00efve patients and populations at risk. J Psychiatry Neurosci 24:304\u2013314","journal-title":"J Psychiatry Neurosci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-006-0570-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-006-0570-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-006-0570-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:31:29Z","timestamp":1558629089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-006-0570-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,22]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3,2]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s00213-006-0570-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,22]]}}}